3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
153
Carboplatin
123
Bevacizumab
87
Cisplatin
66
pembrolizumab
58
Taxes
51
Gemcitabine
51
liposomal doxorubicin
39
Topotecan
37
olaparib
31
Immunoglobulin G
27
Disulfides
26
Cyclophosphamide
24
Brachytherapy
22
Docetaxel
21
human papillomavirus vaccine, L1 type 16, 18
20
niraparib
19
Platinum
19
Nivolumab
18
Magnetic Resonance Spectroscopy
18
1,2-diaminocyclohexaneplatinum II citrate
18
rucaparib
17
durvalumab
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
16
Doxorubicin
16
Radiotherapy, Intensity-Modulated
14
Radiation
13
Albumin-Bound Paclitaxel
13
fludarabine phosphate
12
fludarabine
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Referral and Consultation
×
Gynecologic
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts